Is Ambrx Biopharma Inc. (AMAM) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 02/20/24
AMBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ambrx Biopharma, Inc. - AMAMBusiness Wire • 02/10/24
AMAM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Ambrx Biopharma, Inc. Is Fair to ShareholdersBusiness Wire • 01/08/24
Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of CancerBusiness Wire • 01/08/24
Ambrx Provides Update On APEX-01, an On-Going Phase 1 / 2 Dose Escalation Study Evaluating ARX517, a Proprietary PSMA-Targeting ADC, in Metastatic Castration-Resistant Prostate CancerGlobeNewsWire • 11/28/23
Ambrx: Next-Generation Antibody-Drug Conjugates, Buying The Dip After ESMO DataSeeking Alpha • 10/24/23
Ambrx Announces ARX517, a PSMA-Targeted ADC, Demonstrates a Promising 52% PSA50 (≥50% Reduction) and a Highly Differentiated Safety and PK Profile in Patients with mCRPC, who Progressed on Multiple FDA-Approved TreatmentsGlobeNewsWire • 10/23/23
Ambrx Provides Safety and Efficacy Data from Ongoing Phase 1/2 APEX-01 Trial of ARX517 in mCRPC at ESMO CongressGlobeNewsWire • 10/16/23
Ambrx to Host KOL Event Discussing ARX517 Data Presented at ESMO Congress 2023GlobeNewsWire • 09/26/23
Ambrx to Present at the Baird and Morgan Stanley Global Healthcare ConferencesGlobeNewsWire • 09/05/23
Ambrx Biopharma Has Surged 483% This Year. But It Could Just Be Getting Started.Investors Business Daily • 08/31/23
Is Ambrx Biopharma (AMAM) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 08/23/23
Ambrx to Present Preliminary ARX517 First-in-Human Safety, Efficacy, and Pharmacokinetics Data at ESMO 2023GlobeNewsWire • 07/28/23